These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 31107995)
1. Pediatric intensive care unit admission due to respiratory syncytial virus: Retrospective multicenter study. Kang JM; Lee J; Kim YK; Cho HK; Park SE; Kim KH; Kim MJ; Kim S; Kim YJ Pediatr Int; 2019 Jul; 61(7):688-696. PubMed ID: 31107995 [TBL] [Abstract][Full Text] [Related]
2. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Romero JR Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452 [TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus morbidity, premorbid factors, seasonality, and implications for prophylaxis. Hon KL; Leung TF; Cheng WY; Ko NM; Tang WK; Wong WW; Yeung WH; Chan PK J Crit Care; 2012 Oct; 27(5):464-8. PubMed ID: 22227087 [TBL] [Abstract][Full Text] [Related]
5. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use. Prais D; Schonfeld T; Amir J; Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282 [TBL] [Abstract][Full Text] [Related]
6. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience. Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996 [TBL] [Abstract][Full Text] [Related]
7. Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases. Shmueli E; Goldberg O; Mei-Zahav M; Stafler P; Bar-On O; Levine H; Steuer G; Mussaffi H; Gendler Y; Blau H; Prais D Pediatr Pulmonol; 2021 Jul; 56(7):2204-2211. PubMed ID: 33913611 [TBL] [Abstract][Full Text] [Related]
8. Epidemiology and risk factors for severe respiratory syncytial virus infections requiring pediatric intensive care admission in Hong Kong children. Leung TF; Lam DS; Miu TY; Hon KL; Chau CS; Ku SW; Lee RS; Chow PY; Chiu WK; Ng DK; Infection; 2014 Apr; 42(2):343-50. PubMed ID: 24277597 [TBL] [Abstract][Full Text] [Related]
9. A multicenter investigation of respiratory syncytial viral infection in children with hematopoietic cell transplantation. Rowan CM; Gertz SJ; Zinter MS; Moffet J; Bajwa RPS; Barnum JL; Kong M; Transpl Infect Dis; 2018 Jun; 20(3):e12882. PubMed ID: 29573141 [TBL] [Abstract][Full Text] [Related]
10. Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Purcell K; Fergie J Pediatr Infect Dis J; 2004 May; 23(5):418-23. PubMed ID: 15131464 [TBL] [Abstract][Full Text] [Related]
11. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
12. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Thorburn K Arch Dis Child; 2009 Feb; 94(2):99-103. PubMed ID: 18653625 [TBL] [Abstract][Full Text] [Related]
13. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease. Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912 [TBL] [Abstract][Full Text] [Related]
14. Neonatal outcomes following new reimbursement limitations on palivizumab in Italy. Belleudi V; Trotta F; Pinnarelli L; Davoli M; Addis A Arch Dis Child; 2018 Dec; 103(12):1163-1167. PubMed ID: 30217858 [TBL] [Abstract][Full Text] [Related]
15. RSV prophylaxis guideline changes and outcomes in children with congenital heart disease. Walpert AS; Thomas ID; Lowe MC; Seckeler MD Congenit Heart Dis; 2018 May; 13(3):428-431. PubMed ID: 29436781 [TBL] [Abstract][Full Text] [Related]
16. The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study. Butt ML; Symington A; Janes M; Elliott L; Steele S; Paes BA Eur J Pediatr; 2011 Jul; 170(7):907-13. PubMed ID: 21174120 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Hampp C; Kauf TL; Saidi AS; Winterstein AG Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647 [TBL] [Abstract][Full Text] [Related]
18. Restrictive Palivizumab Use Does Not Lead to Increased Morbidity and Mortality in Pediatric Hematopoietic Stem Cell Transplantation Patients. Teusink-Cross A; Davies SM; Danziger-Isakov L; El-Bietar J; Grimley MS Biol Blood Marrow Transplant; 2016 Oct; 22(10):1904-1906. PubMed ID: 27422147 [TBL] [Abstract][Full Text] [Related]
19. RSV outbreak in a paediatric intensive care unit. Thorburn K; Kerr S; Taylor N; van Saene HK J Hosp Infect; 2004 Jul; 57(3):194-201. PubMed ID: 15236847 [TBL] [Abstract][Full Text] [Related]
20. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]